P533 Correlation of endoscopic and clinical endpoints during induction therapy in patients with moderate-to-severe Crohn’s disease: Analysis from CELEST study
William J. Sandborn(University of San Diego), Ana P. Lacerda(AbbVie (United States)), Fabio Cataldi(Pfizer (United States)), James D. Lewis(University of Pennsylvania), S Goteti(AbbVie (United States)), Silvio Danese(IRCCS Ospedale San Raffaele), David T. Rubin(University of California System), Wen Zhou(Merck & Co., Inc., Rahway, NJ, USA (United States)), Qing Zhou(AbbVie (United States)), B. Feagan, Walter Reinisch(Medical University of Vienna)
Cited by 3
Related Papers
Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes
|Science|2011|6.6k
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
|Nature Medicine|2013|4.4k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k